From data to models : reducing uncertainty in benefit risk assessment : application to chronic iron overload in children

Bellanti, F.

Acknowledgments

The past few years that I spent at the Division of Pharmacology in Leiden happened to overlap with a period of substantial turnaround of staff and students. This gave me the chance to get to know quite a large group of people with whom I have not only shared my time at the department but most importantly also ideas and experience. In a way or another, this interaction led them undoubtedly to contribute to the work described in this thesis. As the list would probably fill this whole page, so I prefer to simply recognise everyone's contribution with a big Thank You!

I would like to make a special reference to my supervisors, Oscar and Meindert, for the brilliant ideas and the guidance they have provided me with during this challenging journey. I am also thankful to three students I had the privilege to supervise: Annette, Morris and Rob; they have contributed with great enthusiasm and effort to the work described in chapters 1, 6 and 8, which provided the basis for the development of almost all the concepts of this thesis. Last but not least, I would like to thank my paranimphs Chiara and Sven for always being there. I am grateful for having met you guys, you have been during this whole period and still are not only a huge support but above all very good friends.

Se oggi ho avuto la possibilità di raggiungere anche questo traguardo lo devo soprattutto alle persone che mi stanno vicino e che mi hanno permesso di crescere ogni giorno: la mia Famiglia. Grazie!

Curriculum vitae

Francesco Bellanti was born in Messina, Italy, on the 10th of January 1986. He obtained his scientific diploma in 2004 at the Liceo Scientifico “G. Seguenza” in Messina. Subsequently he started his training in Pharmaceutical Chemistry and Technology at the Faculty of Pharmacy of the University of Messina, where he received his MSc degree in 2010.

Immediately after the completion of this undergraduate training in 2009, he joined the Division of Pharmacology of the Leiden Academic Centre for Drug Research (LACDR) under the supervision of Prof. Oscar Della Pasqua for the Task Force in Europe for Drug Development for the Young (TEDDY), a network of Excellence funded under the Sixth EU Framework Programme for Research and Technological Development. During this period he contributed to the evaluation of pharmacogenetic factors on the treatment of neuroblastoma as well as on the relevance of modelling and simulation to paediatric drug development.

In 2011 he obtained the license to practice as a pharmacist in Italy and started his PhD research programme at the LACDR under the supervision of Prof. Meindert Danhof and Prof. Oscar Della Pasqua, which led to this thesis. Within his PhD programme he was responsible for the planning, design and implementation of the DEEP-1 multi-centre pharmacokinetic study of deferiprone in children younger than 6 years of age, which was successfully concluded in February 2014.

Since February 2015 he works as a modeller consultant for Quantitative Solutions B.V.

List of Publications

Bellanti F, Del Vecchio GC, Putti MC, Cosmi C, Fotzi I, Bakshi SD, Danhof M, and Della Pasqua O. Model-based optimisation of deferoxamine chelation therapy. Pharm Res. [In press]

Bellanti F, van Wijk RC, Danhof M, Della Pasqua O. Integration of PKPD relationships into Benefit Risk Analysis. Br J Clin Pharmacol. 2015 May 5 [Epub ahead of print].

Bellanti F, Danhof M, Della Pasqua O. Population pharmacokinetics of deferiprone in healthy subjects. Br J Clin Pharmacol. 2014 Dec; 78(6):1397-406.

Bellanti F, Kågedal B, Della Pasqua O. Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma? Eur J Clin Pharmacol. 2011 May;67 Suppl 1:87-107

Bellanti F, Della Pasqua O. Modelling and simulation as research tools in paediatric drug development. Eur J Clin Pharmacol. 2011 May;67 Suppl 1:75-86